R3TA

Peptoris Labs

R3TA

£100.00

Plan your course

Not sure of the dose? Use the figure from this product's research protocol and choose whether it is per day or per week below.

Dose Frequency Course length

— vial(s) needed at — vial size

Estimate only — based on a steady dose at your chosen frequency and selected vial size. Titration may use less in early weeks. For research use only, not medical advice.

Description

R3TA is a groundbreaking investigational peptide represents the next evolution in obesity and type 2 diabetes pharmacotherapy. Unlike previous weight loss medications that target one or two metabolic pathways, R3TA is the first triple receptor agonist that simultaneously activates three key hormonal pathways: GLP-1, GIP, and glucagon receptors.

First publicly identified around 2019, R3TA has generated significant attention in the medical community after demonstrating unprecedented weight loss results in clinical trials with participants losing up to 24.2% of their body weight in 48 weeks, surpassing the efficacy of current market-leading medications like semaglutide and tirzepatide 

As obesity affects over 42% of American adults and is linked to numerous comorbidities including cardiovascular disease, type 2 diabetes, and certain cancers, the development of more effective pharmacological interventions like retatrutide addresses a critical public health need.

 

Retatrutide — 30mg protocol. Edit the doses below for the 30mg vial.

Quickstart Highlights

Retatrutide is an investigational triple-receptor agonist peptide (targets GLP-1, GIP, and glucagon receptors) under development for obesity and type 2 diabetes[1][2]. Phase 2 trials demonstrated remarkable weight-loss efficacy, with patients losing up to 24% of body weight at 48 weeks on higher doses[3][4].

Storage Instructions

Proper storage preserves peptide quality and stability.

  • Lyophilized: Store at −20 °C (−4 °F) or colder in dry, dark conditions; stable for up to 24 months[16].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks[16].
  • Allow vials to reach room temperature before opening to reduce condensation.
  • For extended storage, aliquot reconstituted solution and freeze at −20 °C (−4 °F); thaw only once before use[17].

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container[14].
  • Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and lipohypertrophy[13].
  • For volumes >1.0 mL, split into 2 separate injections at different sites for better absorption[5].
  • Inject slowly; wait a few seconds before withdrawing the needle to ensure full dose delivery.
  • Document weekly dose, date, and injection sites to maintain consistency.
  • Gradual titration is essential to minimize gastrointestinal side effects; never skip escalation steps[6].

How It Works

Retatrutide’s unique mechanism of action stems from its triple-agonist design. By activating GLP-1 and GIP receptors, it enhances insulin secretion (when glucose is present) and suppresses appetite, similar to existing incretin therapies[7][8]. Additionally, Retatrutide’s glucagon receptor agonism raises metabolic rate and promotes energy expenditure, further amplifying fat burning and weight loss beyond GLP-1/GIP effects alone[7]. The peptide is engineered with a fatty-acid moiety to extend its circulation time (half-life ~6 days), allowing for once-weekly dosing[2]. The combined hormonal activation leads to reduced calorie intake, increased satiety, and enhanced lipid oxidation, yielding potent weight loss and glycemic control[8][9]. Preclinical studies confirmed that adding glucagon activity helps counteract the body’s adaptive slowing of metabolism during weight loss[7]. In essence, Retatrutide tackles three metabolic pathways at once, resulting in greater efficacy in lowering blood glucose and body fat than single- or dual-agonist therapies.

Potential Benefits & Side Effects

Observations from Phase 2 human clinical trials.

Benefits

  • Exceptional weight loss: Patients with obesity (without diabetes) lost an average of 22–24% of body weight at 48 weeks on 8–12 mg doses[3][4].
  • Glycemic control: In type 2 diabetes patients, HbA1c dropped by 1.3–2.0% (from ~8.0% to ~6.0%) with 4–12 mg doses[1]; ~82% reached HbA1c ≤6.5%.
  • Cardiometabolic improvements: Reductions in blood pressure, LDL cholesterol, waist circumference, and liver fat content (>80% resolution of hepatic steatosis on high doses)[10][11].
  • Universal response: 100% of participants on 8–12 mg achieved at least 5% weight reduction[4].

Side Effects

  • Gastrointestinal symptoms: Most common adverse effects were mild-to-moderate nausea, vomiting, and diarrhea, occurring primarily during dose escalation[6][12].
  • Side effects were dose-dependent and transient; gradual titration (4-week intervals) significantly reduced GI discomfort compared to rapid escalation[6].
  • No severe hypoglycemia or serious treatment-related adverse events reported in trials[1][2].
  • Safety profile comparable to GLP-1 agonists when properly titrated[12].

 

References

Certificate of Analysis

Every batch of R3TA is independently lab-tested to a minimum of 98% purity. A Certificate of Analysis is available on request — contact us with your order or lot number and we'll send the COA for your specific batch.

Request a COA

Research Protocol

Full dose-by-dose reconstitution & dosing protocol for R3TA.

View Research Protocol →

For laboratory and scientific research use only. Not medical advice.

For laboratory and research use only. Minimum 98% purity. Supplied in sterile, flip-top headspace vials for laboratory use. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. The purchaser accepts full responsibility for safe handling, storage and lawful use.